Bruker (BRKR) Cash & Equivalents (2009 - 2026)

Bruker (BRKR) has 18 years of Cash & Equivalents data on file, last reported at $133.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 27.58% year-over-year to $133.4 million; the trailing twelve-month figure through Mar 2026 stood at $133.4 million (down 27.58% YoY), and the FY2025 full-year result was $298.8 million, up 62.92% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $133.4 million, down from $298.8 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $816.1 million in Q1 2022 and bottomed at $92.0 million in Q2 2025.
• The 5-year median for Cash & Equivalents is $340.1 million (2024), against an average of $392.8 million.
• The widest annual swing landed in 2024, when Cash & Equivalents tumbled 70.48%; it then soared 97.91% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $645.5 million in 2022, then decreased by 24.35% to $488.3 million in 2023, then plunged by 62.44% to $183.4 million in 2024, then surged by 62.92% to $298.8 million in 2025, then slumped by 55.35% to $133.4 million in 2026.
• The last three Cash & Equivalents figures came in at $133.4 million (Q1 2026), $298.8 million (Q4 2025), and $293.1 million (Q3 2025), per Business Quant data.

Peer Comparison